explore -WSS

explore

author：hotspot 2025-09-30 00:35:12 - browse：8

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

focus

WSS

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

In same hospitals, Black patients receive fewer opioids than white patients

In same hospitals, Black patients receive fewer opioids than white patients

Readout Newsletter: Beam, Prozac, "TechBio" and more

Wegovy trial has doctors encouraged over new possibilities

FDA panel issues narrow recommendation for Covid vaccine booster doses

Wikipedia

explore

Wikipedia

New air purifier tech could be key to improving indoor air quality

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Hollywood unions extend contract negotiations for actors

Laying a path for careers in science

Duchenne breakthrough therapy leaves behind pioneering families

Neuroscience renaissance leads to new crop of psychiatric drugs

Drug repurposing or repositioning? The language matters

How to use technology to prevent future drug shortages

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Neuroscience renaissance leads to new crop of psychiatric drugs

focus

FDA panel issues narrow recommendation for Covid vaccine booster doses

5 ways to address the shortage of health care workers

Children’s Hospital revives plan for pedestrian bridge

Redefining sustainability for the pharmaceutical industry

Anavex keeps shifting the goalposts in its clinical trials

In same hospitals, Black patients receive fewer opioids than white patients

leisure time

focus

hotspot

knowledge